



MEDIGARD LIMITED
Suite 14, 30 Tedder Avenue, Main Beach QLD 4217 Australia
Telephone +61 7 5578 7822; Fax +61 7 5528 4459
E-mail: office@medigard.com.au www.medigard.com.au
ABN 49 090 003 044

ASX ANNOUNCEMENT

21 November 2017

Medigard Appointment of Dr Ian Dixon as Executive Director

Today Dr Chris Bishop, Chairman of Medigard Limited, announced that Dr Ian Dixon has agreed to join the Board of Medigard as an Executive Director.

Through the review of business and technology opportunities Medigard has engaged with Melbourne-based Dr Dixon and his Melbourne-based biotechnology team operating as the private Altnia Group.

Over the past 12 months the Board of Medigard has been investigating ways that it might broaden its R&D and commercialisation activities in the life-sciences field whilst maintaining and expanding activities in syringe technology and its strategic alliance with SOL-MILLENNIUM.

Dr Bishop said “Medigard shareholders support Medigard as an innovator in the medical field – and our focus on using advanced technology to improve people’s lives and deliver commercial outcomes.”

Dr Dixon and the Altnia Group have a track record of building value in innovative medical-related products and technologies – and this appointment allows Medigard to access and harness this capability.

Dr Dixon is a non-executive director of Noxopharm (ASX-CYP) – a clinical-stage company with a market capitalisation of around \$60m. He is a major shareholder in Nyrada – a USA-based company spun out by Noxopharm in October '17 and including his Altnia PCSK9 drug project. He is also the co-founder of Cynata Inc in 2011, the company which has become Cynata Therapeutics Ltd (ASX-CYP) – a clinical-stage regenerative medicine company with a market capitalisation of around \$60m and a strategic partnership with Fuji Film.

Dr Dixon has a PhD in biomedical engineering from Monash University, an MBA and other professional qualifications and memberships. Ian's main focus has been on commercialising technologies and building enterprise-value through careful investment and in-house innovation.

Dr Dixon said "I am pleased to join the Medigard team and help them build Medigard into a success-story through careful investment into a range of promising and exciting opportunities we have under review."

Medigard Ltd has a loyal group of shareholders who support Medigard's focus on the medical field.

Dr Dixon said "We have identified some significant opportunities in the syringe field and intend to move into higher-value products such as prefilled-syringes. We will be looking at innovations from Australian researchers and selecting the most promising technologies to push through to commercialisation and sales. I already have some wonderful collaborations in this field and Medigard gives us a platform to accelerate this type of activity."

The key terms of the appointment are set out in Schedule 1.

Ian is available at ian.dixon@medigard.com.au phone + 613 9894 4555 (local 03 9894 4555) or mobile 0418 561 907.

PATRICIA BOERO

Company Secretary

SCHEDULE 1

Summary of key terms of engagement

Commencement date	21 November 2017
Services	Direct involvement in the management of the Company's business and the administration of the Company's business affairs
Total Employment Cost	Initial total employment cost \$240,000 per annum to be reviewed at least annually
Incentive	Subject to shareholder approval, sign on incentive of (1) 40,000,000 options to acquire fully paid ordinary shares in the Company, each with an exercise price of \$0.10 expiring on the fifth anniversary of the issue of those options and (2) 40,000,000 options to acquire fully paid ordinary shares in the Company, each with an exercise price of \$0.20 expiring on the fifth anniversary of the issue of those options.